SCHEMBL3397155

SCHEMBL3397155

COc1ccc(Nc2ncc(NC(=O)c3ccc(OC)cc3)s2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 4/20 0.60
CSNK2A1 P68400 4/20 0.60
NPC1 O15118 6/20 0.56
RAB9A P51151 6/20 0.56
TP53 P04637 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
ALOX15 P16050 1/20 0.56
ALDH1A1 P00352 3/20 0.54
KMT2A Q03164 2/20 0.53
POLB P06746 2/20 0.53
LMNA P02545 2/20 0.52
KDM4E B2RXH2 1/20 0.51
CYP1A2 P05177 1/20 0.51
MEN1 O00255 1/20 0.51
MAPK13 O15264 1/20 0.51
MAPK12 P53778 1/20 0.51
MAPK11 Q15759 1/20 0.51
MAPK14 Q16539 1/20 0.51
PPARG P37231 1/20 0.50
TDP1 Q9NUW8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3393588 0.94 CSNK2A2 (0.55) CSNK2A2CSNK2A1NPC1RAB9ATP53
SCHEMBL3394933 0.94 CSNK2A2 (0.60) CSNK2A2CSNK2A1NPC1RAB9ASMN1; SMN2
SCHEMBL3396818 0.93 CSNK2A2 (0.56) CSNK2A2CSNK2A1NPC1RAB9ATP53
SCHEMBL3396383 0.92 CSNK2A2 (0.55) CSNK2A2CSNK2A1NPC1RAB9ATP53
SCHEMBL3393872 0.91 CSNK2A2 (0.52) CSNK2A2CSNK2A1NPC1RAB9ATP53
SCHEMBL3397310 0.90 CSNK2A2 (0.56) CSNK2A2CSNK2A1NPC1RAB9ATP53
SCHEMBL3397141 0.90 CSNK2A2 (0.51) CSNK2A2CSNK2A1NPC1RAB9ATP53
SCHEMBL3393212 0.90 TNIK (0.56) CSNK2A2CSNK2A1NPC1RAB9ATP53
SCHEMBL3398669 0.89 CSNK2A2 (0.49) CSNK2A2CSNK2A1NPC1RAB9ATP53
SCHEMBL3393897 0.87 TNIK (0.49) CSNK2A2CSNK2A1NPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216795-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216795-A1 TNIK INHIBITOR AND THE USE TNIK, TNNI3K, TNK1 CSNK2A2 18/4885CSNK2A1 24/4885NPC1 2281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.